Berrazueta et al., 1997 - Google Patents

Dose‐and time‐dependency of the dilator effects of the endothelin antagonist, BQ‐123, in the human forearm

Berrazueta et al., 1997

Document ID: 17363072451022528199
Author: Berrazueta J; Bhagat K; Vallance P; MacAllister R
Publication year: 1997
Publication venue: British journal of clinical pharmacology

External Links

Cited by

Snippet

Aims Endothelin‐1 is a potent endogenous vasoconstrictor that acts on the endothelin A (ETA) receptor. The dose‐response and time‐course of the dilator effect of the ETA receptor antagonist, BQ‐123, was investigated in the forearm of healthy volunteers. Methods Forearm …

Continue reading at bpspubs.onlinelibrary.wiley.com (PDF) (other versions)

210000000245 Forearm 0 title abstract description 25

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/06—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radiowaves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body

Similar Documents

Publication	Publication Date	Title
Berrazueta et al.	1997	Dose‐and time‐dependency of the dilator effects of the endothelin antagonist, BQ‐123, in the human forearm
EP1082112B1 (en)	2008-04-09	Endogenous nitric oxide synthesis under conditions of low oxygen tension
Fukuda et al.	2001	Mechanisms of TNF-α stimulation of amiloride-sensitive sodium transport across alveolar epithelium
Haynes et al.	1994	Contribution of endogenous generation of endothelin-1 to basal vascular tone
Calver et al.	1991	Dilator actions of arginine in human peripheral vasculature
Creager et al.	1992	L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans.
Wiest et al.	1999	Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility
Claria et al.	1991	Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites
Smit et al.	2013	Helium induces preconditioning in human endothelium in vivo
PT1112075E (en)	2006-12-29	Compositions for the treatment of male erectile dysfunction
Fräßdorf et al.	2010	Sevoflurane-induced preconditioning: impact of protocol and aprotinin administration on infarct size and endothelial nitric-oxide synthase phosphorylation in the rat heart in vivo
Angeli et al.	1994	Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites
Pearl et al.	1999	Bosentan prevents hypoxia-reoxygenation–induced pulmonary hypertension and improves pulmonary function
Murton et al.	1998	Hormone responses to stress in patients with major burns
Nathan et al.	2000	Plasma interleukin-4, interleukin-10, and interleukin-13 concentrations and complications after coronary artery bypass graft surgery
Pentel et al.	1988	Effects of high dose alpha-1-acid glycoprotein on desipramine toxicity in rats.
Schwarzenberger et al.	1998	Perioperative cytokine release during coronary artery bypass grafting in patients of different ages
Kopp et al.	2002	PGE2 increases release of substance P from renal sensory nerves by activating the cAMP-PKA transduction cascade
Oda et al.	2007	Acute lung injury and multiple organ dysfunction syndrome secondary to intra-abdominal hypertension and abdominal decompression in extensively burned patients
Zsoter et al.	1970	Mechanism of antihypertensive action of prolonged administration of hydrochlorothiazide in rabbit and dog
Paller et al.	1984	Mechanism of decreased vascular reactivity to angiotensin II in conscious, potassium-deficient rats.
Singh et al.	2019	Adrenaline improves platelet reactivity in ticagrelor-treated healthy volunteers
Brechue et al.	1993	A comparison between the effect of topical and systemic carbonic anhydrase inhibitors on aqueous humor secretion
Espiner	1987	The effects of stress on salt and water balance
Mannucci	1974	Enhancement of plasminogen activator by vasopressin and a drenaline: a role of cyclic AMP?